MicroSintesis closes equity investment, targets 'new era of microbiome products'

摘要

Canadian firm MicroSintesis has received a Can$16.4 million ($12.5 million) minority-stake investment to scale-up production of the company's microbiome platform. The funding was provided by Toronto-based Northern Private Capital (NPC), which is an equity investment vehicle for CFFI Ventures.MicroSintesis is developing what it calls proteobiotics -compounds made of protein sources containing probiotic molecules. The company will utilize the funding to scale-up manufacturing of its products, as well as further develop its platform and research capabilities. The investment will also accelerate the global launch of its products for livestock, companion animals and human health.